Galectin Therapeutics Inc. filings document a clinical-stage biotechnology issuer developing galectin-targeted therapeutics, including belapectin for MASH cirrhosis and portal hypertension. Form 8-K reports furnish operating results, financial condition updates, business updates, Regulation FD materials, and clinical-program disclosures tied to NAVIGATE trial presentations and corporate presentations.
The company’s proxy and governance filings cover director elections, advisory votes on executive compensation, auditor ratification, board changes, officer compensation arrangements, and annual meeting results. Its SEC records also identify GALT common stock registered on The Nasdaq Stock Market and include risk-factor references related to forward-looking clinical development and financing needs.
Galectin Therapeutics Inc. director and more than 10% owner associated with 10X Fund, L.P. reported recent changes in holdings. On 11/24/2025, 24,000 shares of common stock were transferred in an in-kind distribution to a withdrawing limited partner of 10X Fund, L.P., with no consideration received, which is described as exempt from short-swing profit rules. On 12/16/2025, 30,681 common shares were sold in multiple transactions at a weighted average price of $6.66 per share, with individual trade prices ranging from $6.64 to $6.69. After these transactions, the reporting entities show beneficial ownership of 5,614,457 Galectin Therapeutics shares held directly by 10X Fund, L.P., with 10X Capital Management, LLC and James C. Czirr reporting potential indirect ownership through their roles.
Galectin Therapeutics director Jack W. Callicutt reported option exercises and related stock sales under a Rule 10b5-1 trading plan adopted on August 29, 2025. On December 12, 2025, he exercised stock options to acquire 19,793 common shares at an exercise price of $4.16 and sold 19,793 shares at a weighted average price of $6.274, leaving 11,206 shares held directly.
On December 15, 2025, he exercised options to acquire 8,417 shares at $4.16 and sold 8,417 shares at a weighted average price of $6.3, with 11,206 Galectin Therapeutics shares shown as beneficially owned directly after the reported transactions. The options exercised have a $4.16 exercise price, vested 25% on June 30, 2018, 25% on September 30, 2018, and 50% on December 31, 2018, and expire on May 22, 2028.
Galectin Therapeutics Inc. reported the results of its 2025 Annual Meeting of Stockholders held on December 3, 2025. Stockholders elected all nominated directors to serve until the next annual meeting or until their successors are elected and qualified, with each nominee receiving more votes for than withheld.
Stockholders approved a non-binding advisory resolution on executive compensation, with 25,260,489 votes for, 639,415 against and 310,420 abstentions, alongside 19,513,532 broker non-votes. In a separate advisory vote on how often to hold future say-on-pay votes, 22,075,944 votes favored a three-year frequency, and the Board determined that advisory votes on named executive officer compensation will be held every three years. Stockholders also ratified the selection of Cherry Bekaert LLP as the company’s independent registered public accounting firm for the year ending December 31, 2025, with 45,458,024 votes for, 142,268 against and 123,564 abstentions.
Galectin Therapeutics Inc. (GALT) reported insider transactions by its President and CEO, who is also a director. On November 17, 2025, the executive exercised stock options to buy 15,680 shares of common stock at $2.39 per share and sold the same number of shares at a weighted average price of $6.0359. On November 18, 2025, the executive similarly exercised options for 6,783 shares at $2.39 and sold those shares at a weighted average price of $6.1511. After these transactions, the executive directly owned 832,592 common shares and indirectly held 2,000 shares as custodian for a minor child. The filing notes that the trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on April 17, 2025, and that the options exercised had vested fully on December 14, 2018.
Galectin Therapeutics Inc. (GALT) CFO Jack W. Callicutt reported multiple option exercises and related stock sales. On November 17 and 18, 2025, he exercised several stock options to buy common shares at exercise prices of $1.98, $1.11, and $1.23 per share, then sold the exercised shares on the same days.
Sale prices were reported as weighted averages of about $6.0317 on November 17 and $6.223 on November 18, with individual trades ranging from $6.00 to as high as $6.30. After these transactions, Callicutt directly owned 7,614 shares of Galectin common stock. The filing states that all trades were made under a Rule 10b5‑1 trading plan adopted on April 17, 2025.
Galectin Therapeutics Inc. filed an 8-K stating it furnished a press release with results of operations and financial condition for the nine months ended September 30, 2025, along with a business update. The information under Item 2.02 is furnished, not filed, and the press release is attached as Exhibit 99.1 dated November 14, 2025.
Galectin Therapeutics (GALT) filed its Q3 2025 10‑Q, reporting a net loss of $8.184M for the quarter and $25.336M for the nine months. Operating expenses for the nine months fell to $16.720M from $30.005M a year ago as R&D tapered with trial activity.
Cash and equivalents were $11.525M at Sept 30, 2025. Net cash used in operations was $17.833M, partly offset by $14.238M from financing, including related‑party credit draws and $2.071M via the at‑the‑market program. The company states substantial doubt about its ability to continue as a going concern, though it believes existing cash and a new $10M line of credit signed on July 8, 2025 can fund planned operations through June 30, 2026.
Total assets were $12.865M against liabilities of $136.445M, resulting in a stockholders’ deficit of $125.303M. The NAVIGATE trial’s top‑line showed a 49.3% variceal incidence reduction in the per‑protocol population at 2 mg/kg (p<0.05); U.S. completers saw a 68.1% reduction (p=0.02). Safety remained comparable to placebo with no drug‑related SAEs reported.
Galectin Therapeutics (GALT) CEO and Director reported a Rule 10b5-1 trade. On 11/10/2025, he exercised 1,867 stock options at $2.39 and sold 1,867 common shares at a weighted average price of $6.0269 (sales ranged from $6.00 to $6.12). The exercised options were granted on 12/14/2018 and vested 100%.
Following the transactions, he beneficially owns 832,592 shares directly, plus 2,000 shares indirectly as custodian for a minor child. He also reports 22,363 derivative securities (options) beneficially owned.
Galectin Therapeutics (GALT) CFO Jack W. Callicutt reported option exercises and same‑day sales on 11/10/2025 under a Rule 10b5‑1 plan adopted on April 17, 2025. He exercised stock options for 5,291 shares (strike prices: $1.11, $1.23, and $1.98) and sold the same number of shares in open‑market transactions.
Sales were executed at weighted average prices of $6.022, $6.0266, and $6.0298, with individual trades ranging from $6.00 to $6.14. Following these transactions, he directly owned 7,614 shares of common stock.
Galectin Therapeutics (GALT) reported that it presented results from its NAVIGATE trial at the AASLD 2025 Annual Meeting and posted an updated Corporate Presentation. The company also issued a press release; both materials were provided as Exhibits 99.1 and 99.2.
The materials were furnished under Item 7.01 of a Form 8-K and are not deemed filed under the Exchange Act. The disclosures include forward-looking statements subject to the cautionary notes in the exhibits and other SEC reports.